Celgene

BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China
BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China
CP Wire
BeiGene
Celgene
tislelizumab
China
monoclonal antibodies
Flag link:
Can Celgene's latest Revlimid win reverse the company's bad-news streak?
Can Celgene's latest Revlimid win reverse the company's bad-news streak?
Fierce Pharma
Celgene
Revlimid
clinical trials
Roche
Rituxan
non-Hodgkin lymphoma
Flag link:
Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test
Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test
Endpoints
Celgene
BeiGene
tiselizumab
Hodgkin's lymphoma
Flag link:
7 companies to watch during Q2 earnings
7 companies to watch during Q2 earnings
Biopharma Dive
earnings
Biogen
Gilead Sciences
Amgen
Celgene
AbbVie
Pfizer
Spark Therapeutics
Flag link:
Novartis' MS patent win also a win for Celgene's impending MS drug: analyst
Novartis' MS patent win also a win for Celgene's impending MS drug: analyst
Medical Marketing and Media
Celgene
Novartis
ozanimod
Gilenya
MS
multiple sclerosis
patents
Flag link:
Takeda, Celgene Invest $6 Million in Presage Biosciences Cancer Testing Technology
Takeda, Celgene Invest $6 Million in Presage Biosciences Cancer Testing Technology
BioSpace
Presage Biosciences
Takeda
Celgene
cancer
diagnostics
Flag link:
Many Drugmakers Ignore Trump—and Raise Prices Anyway
Many Drugmakers Ignore Trump—and Raise Prices Anyway
Bloomberg
drug pricing
Donald Trump
Pfizer
Celgene
Roche
Novo Nordisk
Flag link:
MS patent win boosts Novartis’ Gilenya, helps Celgene and maybe Biogen too
MS patent win boosts Novartis’ Gilenya, helps Celgene and maybe Biogen too
Fierce Pharma
patents
Novartis
MS
Gilenya
Celgene
exclusivity
Flag link:
Celgene tweaks trial of myeloma CAR-T bb2121, raising dose
Celgene tweaks trial of myeloma CAR-T bb2121, raising dose
Fierce Biotech
Celgene
clinical trials
bb2121
Bluebird Bio
Multiple Myeloma
CAR-T
Flag link:
With Revlimid and Pomalyst price increases, could Celgene be next on Trump’s to-call list?
With Revlimid and Pomalyst price increases, could Celgene be next on Trump’s to-call list?
Fierce Pharma
Pfizer
Celgene
drug pricing
Donald Trump
Revlimid
Pomalyst
Flag link:
A 7-year-old alliance between Celgene and Acceleron is paying off with more promising PhIII data for luspatercept
A 7-year-old alliance between Celgene and Acceleron is paying off with more promising PhIII data for luspatercept
Endpoints
Celgene
Acceleron
beta thalassemia
luspatercept
Flag link:
More than $100 Billion Spent on M&A in the First 6 Months of 2018
More than $100 Billion Spent on M&A in the First 6 Months of 2018
BioSpace
M&A
biotech
Celgene
Sanofi
Impact Biomedicines
Bioverativ
GSK
Takeda
Shire
JNJ
Flag link:
3 Best Biotech Acquisitions of 2018 (So Far)
3 Best Biotech Acquisitions of 2018 (So Far)
Motley Fool
M&A
biotech
Celgene
Juno Therapeutics
Novartis
AveXis
Roche
Foundation Medicine
Flag link:
Celgene pledges to limit price hikes—or does it?
Celgene pledges to limit price hikes—or does it?
Fierce Pharma
Allergan
Sanofi
Celgene
drug pricing
Flag link:
Roche vaults into lead in frontline triple negative breast cancer as Tecentriq/Abraxane combo aces progression-free survival
Roche vaults into lead in frontline triple negative breast cancer as Tecentriq/Abraxane combo aces progression-free survival
Endpoints
Roche
Tecentriq
Genentech
triple negative breast cancer
Celgene
Abraxane
Flag link:
Pharma's 2 Biggest Setbacks in 2018
Pharma's 2 Biggest Setbacks in 2018
Motley Fool
AbbVie
Celgene
Rova-T
ozanimod
Flag link:
Acceleron blood disease drug hits goal in pivotal clinical trial
Acceleron blood disease drug hits goal in pivotal clinical trial
Stat
Acceleron
Celgene
luspatercept
clinical trials
myelodysplastic syndrome
Flag link:
Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives
Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives
Yahoo/Benzinga
Bluebird Bio
Celgene
LentiGlobin
Madrigal Pharmaceuticals
Flag link:
Why Impact Biomedicines Could Be Celgene’s Next Embarrassment
Why Impact Biomedicines Could Be Celgene’s Next Embarrassment
NY Shock Exchange
Celgene
Impact Biomedicines
Flag link:
Celgene executive blames Receptos for ozanimod filing fail
Celgene executive blames Receptos for ozanimod filing fail
Fierce Biotech
Celgene
Receptos
ozanimod
Flag link:

Pages